The new accelerator for healthcare ventures, BaseLaunch, wants to link the best start-ups to the Basel region – and in doing so, provide impulses for…
Jérémie Meyer30.03.2017
→ Jean-Paul Clozel has a name for his biotech spinout. Once J&J’s $30 billion deal to acquire Actelion goes through, the R&D side of the…
Jérémie Meyer15.03.2017
Innovation is the key to success for SMEs and start-ups. But they need money for this. One way to develop and maintain innovative business areas…
Jérémie Meyer15.03.2017
The new accelerator for healthcare ventures, BaseLaunch, wants to link the best start-ups to the Basel region – and in doing so, provide impulses for…
Jérémie Meyer15.03.2017
“If we invest billions in university research, then this remains an abortive effort if we do not make sure at the same time that these…
Jérémie Meyer15.03.2017
Genentech, an American subsidiary of the Basel-based pharmaceutical company Roche, will start a second Phase 3 clinical trial for its Alzheimer’s therapy crenezumab.
Jérémie Meyer01.03.2017
The Basel-based venture capital firm BioMedPartners has raised CHF 75 million in the first closing of their fund BioMedInvest III, a healthcare venture capital fund…
Jérémie Meyer17.02.2017
The risk adjusted, net present value (rNPV) method is the standard valuation method used within pharma and biotech companies when valuing assets beyond discovery stage.…
Jérémie Meyer15.02.2017